In December 2025, CMS announced the BALANCE Model — Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth. The name is bureaucratic. The design choice behind it is not. The model enables Medicare Part D plans and state Medicaid agencies to cover GLP-1 medications for weight management. What makes it notable isn't just the expanded…
Tag: Breaking News
Foundayo Lowers the Friction on GLP-1 Access. Here’s What Employers Should Watch.
The FDA yesterday approved Foundayo (orforglipron), Eli Lilly's oral GLP-1 for weight loss. It's the second daily GLP-1 pill to reach the market, following Novo Nordisk's Wegovy pill in December 2025. For anyone tracking the GLP-1 landscape from an employer benefits perspective, this approval matters — not because of the drug itself, but because of…